Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results

Background: Melanoma of unknown primary (MUP) is an uncommon clinical subtype of melanoma of known primary (MKP). Objectives: We aimed to compare treatment outcomes of MUP and MKP patients who had undergone therapy with immune checkpoint inhibitors (ICPI). Methods: We studied 41 metastatic melanoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Gambichler, Thilo, Chatzipantazi, Maria, Schröter, Ulrike, Stockfleth, E., Gedik, Cansu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844308/
https://www.ncbi.nlm.nih.gov/pubmed/31741779
http://dx.doi.org/10.1080/2162402X.2019.1677139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844308/
https://www.ncbi.nlm.nih.gov/pubmed/31741779
http://dx.doi.org/10.1080/2162402X.2019.1677139

Ejemplares similares